⌘K
t
Oxford Nanopore Technologies plc announced the Financial Conduct Authority (FCA) approved the transfer of its ordinary shares' listing category. The transfer moves its shares from the equity shares (transition) category to the equity shares (commercial companies) category on the official list of the FCA, effective 8:00 a.m. GMT on 6 November 2024. This follows an announcement made on 8 October 2024.
| Date | 6 Nov 2024 |
| Time | 07:00:02 |
| Category | Corporate updates |
| ID | 0058L |
THIS ANNOUNCEMENT DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT AND NEITHER THIS ANNOUNCEMENT NOR ANYTHING HEREIN FORMS THE BASIS FOR ANY OFFER TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN THE COMPANY NOR SHALL IT FORM THE BASIS FOR ANY CONTRACT OR COMMITMENT WHATSOEVER.
6 November 2024
Oxford Nanopore Technologies plc
Approval of the transfer of listing category
Further to the announcement on 8 October 2024, Oxford Nanopore Technologies plc is pleased to announce the approval by the Financial Conduct Authority (the "FCA") of the transfer of listing category of its ordinary shares from the equity shares (transition) category to the equity shares (commercial companies) category on the official list of the FCA, in accordance with Rule 21.5 of the UK Listing Rules as modified by Transitional Provision 2 (the "Transfer").
The Transfer will take effect at 8:00 a.m. GMT today.
For further information, please contact:
Oxford Nanopore Technologies plc
Investors: ir@nanoporetech.com
Media: media@nanoporetech.com
Robert Way
Richard Abel
Patrick Evans
+44 (0)20 7500 5000
Teneo (communications adviser to the Company)
Tom Murray
Olivia Peters
+44 (0) 20 7353 4200
OxfordNanoporeTechnologies@teneo.com
About Oxford Nanopore Technologies plc:
Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The Group has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 125 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.
For more information please visit: www.nanoporetech.com
Forward-looking statements
This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.